Novartis: Buy Thesis Fades Into Q1 2026 Results (Rating Downgrade)

Novartis AG ended 2025 on a high note. On February 27, NVS stock reached a 52-week high of $170.46. However, a correction began after that, in my view, partly due to a 33.2% quarter-over-quarter decline in sales of heart failure drug Entresto to $1.25 billion in Q4.